Some types of antiangiogenic multiple receptor tyrosine kinase inhibitors (RTKis) including regorafenib and lenvatinib are considered to reduce tumor-associated macrophages and regulatory T cells in the tumor microenvironment by regulating tumor angiogenesis [99,100]. This evidence concerns the gene NTRK1 and neoplasm.